Unicycive Therapeutics, Inc. - Common Stock (UNCY)

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) of a class action securities lawsuit.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - August 23, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”).

NEW YORK, NY - August 22, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) of a class action securities lawsuit.

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - August 20, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) of a class action securities lawsuit.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.